Preclinical & Translational
- Why ADCs fail in translation, and what would meaningfully improve preclinical predictivity
- Designing the preclinical package backward from the clinical and regulatory question
- The model problem: Do current in vitro and animal systems truly reflect human conjugate behavior?
- Integrating PK/PD, biodistribution, and safety into a single translational story
- How much preclinical evidence is “enough” to justify first-in-human, and who decides
- Translational lessons being read across from the approved ADC clinical experience
- Biomarker-led translation to build patient-selection strategy from the start